LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Strona główna・Stock List・Simulations Plus Inc

Simulations Plus Inc

Closed

SectorHealthcare

16.57 3.24

Buy Sell

Overview

Share price change

24h

Current

Min

16.06

Max

17.03

Key metrics
By Trading Economics
Income	3.9M 4.5M
Sales	5.9M 24M
EPS	0.35
Profit margin	18.669
Employees	212
EBITDA	4.9M 7.2M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	-4.59% downside

Dividends
By Dow Jones
Next Earnings	13 lip 2026

Market Stats
By TradingEconomics
Market Cap	107M 358M
Previous open	13.33
Previous close	16.57

News Sentiment

By Acuity

80%

20%

315 / 344 Ranking in Healthcare

Simulations Plus Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

4 cze 2026, 21:51 UTC

Major Market Movers

Merlin Shares Rally After Defense Department's Design Review Wraps

4 cze 2026, 23:46 UTC

Market Talk

U.S. Jobs Data May Offer Bullish Catalyst for Dollar Vs. Yen -- Market Talk

4 cze 2026, 23:44 UTC

Market Talk

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

4 cze 2026, 23:42 UTC

Acquisitions, Mergers, Takeovers

Energy Resources of Australia: Court to Decide on Rio Tinto Compulsory Acquisition Request

4 cze 2026, 23:41 UTC

Acquisitions, Mergers, Takeovers

Energy Resources of Australia to Enter Trading Halt

4 cze 2026, 23:34 UTC

Market Talk

Oil Edges Lower Amid Mixed Middle East Developments -- Market Talk

4 cze 2026, 23:31 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4 cze 2026, 23:31 UTC

Market Talk

Mercury NZ Loses Bull Despite Sector Earnings Powering Up -- Market Talk

4 cze 2026, 23:31 UTC

Market Talk

Global Equities Roundup: Market Talk

4 cze 2026, 23:08 UTC

Market Talk

Narrowing Rate Differentials Make Australian Dollar Less Attractive Versus USD -- Market Talk

4 cze 2026, 22:41 UTC

Market Talk

Australia Shares Set to Rise at the Open -- Market Talk

4 cze 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

4 cze 2026, 20:44 UTC

Acquisitions, Mergers, Takeovers

RTX Stock Rises After Catching an Upgrade. Why This Analyst Is Bullish. -- Barrons.com

4 cze 2026, 20:16 UTC

Market Talk

Mexican Demand Indicators Show Signs of Life -- Market Talk

4 cze 2026, 20:15 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences And Lakefront Complete Acquisition Of Ouro Medicines To Further Expand Inflammation Pipeline >GILD

4 cze 2026, 19:46 UTC

Market Talk

Treasury Yields Decline Ahead of U.S. Payrolls -- Market Talk

4 cze 2026, 19:38 UTC

Market Talk

Oil Futures Retreat After 3-Session Winning Streak -- Market Talk

4 cze 2026, 19:30 UTC

Market Talk

U.S. Natural Gas Futures Rise on Weather, Storage Data -- Market Talk

4 cze 2026, 18:47 UTC

Acquisitions, Mergers, Takeovers

Google Stock Attracts Cathie Wood's ARK and Berkshire Hathaway. That's Rare. -- Barrons.com

4 cze 2026, 18:38 UTC

Earnings

Money Quote: Tech Weakness in Context -- WSJ

4 cze 2026, 18:24 UTC

Earnings

Quantinuum, Broadcom, UnitedHealth, and More Stocks That Explain Today's Market -- Barrons.com

4 cze 2026, 17:09 UTC

Market Talk

Retest of $55k Seen Possible for Bitcoin -- Market Talk

4 cze 2026, 16:58 UTC

Earnings

Broadcom, UnitedHealth, Blackstone, Ciena, and More Stocks That Explain Today's Market -- Barrons.com

4 cze 2026, 16:46 UTC

Market Talk

Strategy BTC Sale Continues to Weigh on Prices -- Market Talk

4 cze 2026, 16:38 UTC

Earnings

UnitedHealth Stock Rises. Why the Health Insurer Is Leading the Dow to Sharp Gains. -- Barrons.com

4 cze 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

4 cze 2026, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

4 cze 2026, 16:13 UTC

Market Talk

On Again, Off Again Deals Keep Oil Market on Edge -- Market Talk

4 cze 2026, 16:11 UTC

Market Talk

Copper Market Is Awaiting Key U.S. Tariff Decision -- Market Talk

4 cze 2026, 15:56 UTC

Market Talk

Copper Rises Amid Hormuz Disruptions, U.S. Stockpiling -- Market Talk

Peer Comparison

Price change

Simulations Plus Inc Forecast

Price Target

By TipRanks

-4.59% downside

12 Months Forecast

Average 16 USD -4.59%

High 16 USD

Low 16 USD

Based on 3 Wall Street analysts offering 12 month price targets forSimulations Plus Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

3 ratings

Buy

Hold

Sell

Based on 3 analysts giving stock ratings to Simulations Plus Inc - Dist in the past 3 months.

Sentiment

By Acuity

315 / 344 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.